#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow